tbuckley/cabot-search huggingface dataset:
AB0969 Conventional and biologic disease modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomised controlled trials
Authors: M.S.M. Persson, A. Sarmanova, M. Doherty, W. Zhang
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The role of inflammation in osteoarthritis (OA) is controversial. Some perceive OA as a reparative process where modest inflammation is secondary to largely biomechanical insult.<sup>1</sup> In contrast, others believe synovial inflammation to be a central driver of OA pain and progression.<sup>2</sup> This has encouraged randomised controlled trials (RCTs) of conventional and biologic disease modifying anti-rheumatic drugs (DMARDs) in OA. However, it is unknown whether these treatments that are primarily used for rheumatoid arthritis are effective for OA. <h3>Objectives</h3> To examine the efficacy of DMARDs, including biologics, in people with symptomatic OA. <h3>Methods</h3> A systematic literature search was conducted (to November 2017) for placebo-controlled RCTs of DMARDs in OA. Data extraction and Cochrane's risk of bias assessments were conducted independently by two reviewers (MP, AS). Pain relief at treatment peak time-point was combined using a random-effects meta-analysis. All DMARDs were pooled and sensitivity analysis was undertaken for high-quality trials and subgroup analyses for DMARD type, biologic target, joint site, OA subtype, and publication type. <h3>Results</h3> Eleven RCTs (n=1205), including six (n=757) for conventional and five (n=448) for biologic DMARDs, were included in the meta-analysis (7 full texts, 4 abstracts). Overall, conventional and biologic DMARDs were marginally superior to placebo. However, statistical superiority was not observed in high-quality studies (table 1) or subgroup analysis for conventional or biologic DMARDs separately (figure 1). Furthermore, no differences were observed between erosive versus non-erosive hand OA, hand versus knee OA, anti-IL1 versus anti-TNF biologics, or full text versus abstract-only publications (table 1). <h3>Conclusions</h3> No significant pain relief was observed from either conventional or biologic DMARDs compared to placebo. Combining all DMARDs gave statistical separation from placebo, but this was below the minimal clinically important difference threshold (0.5 SD) used in the UK.<sup>3</sup> Furthermore, the analysis is based on <i>peak</i> time point for the intervention, so even at their most effective timepoints these treatments do very little over placebo. Lack of efficacy of DMARDs supports the perspective that inflammation is not an important driver for OA pain and differs fundamentally from that in rheumatoid arthritis. <h3>References</h3> [1] Felson DT. Osteoarthritis as a disease of mechanics. Osteoarthritis and cartilage. 2013;21(1):10–15. [2] Robinson WH, et al. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nature Reviews Rheumatology. 201601 Oct;12(10):580–92. [3] NICE. Osteoarthritis: Care and management in adults [CG177]201416/10/2015. <h3>Disclosure of Interest</h3> None declared
Decreased Expression of Vascular Endothelial Growth Factor Receptor 1 Contributes to the Pathogenesis of Hereditary Hemorrhagic Telangiectasia Type 2
Authors: Jérémy H. Thalgott, Damien Dos-Santos-Luis, Anna E. Hosman, Sabrina Martin, Noël Lamandé, Diane Bracquart, Samly Srun, Georgios Galaris, Hetty C. de Boer, Simon Tual-Chalot, Steven Kroon, Helen M. Arthur, Yihai Cao, Repke J. Snijder, Frans Disch, Johannes J. Mager, Ton J. Rabelink, Christine L. Mummery, Karine Raymond, Franck Lebrin
Journal: Circulation (2018)

Background: Hereditary Hemorrhagic Telangiectasia type 2 (HHT2) is an inherited genetic disorder characterized by vascular malformations and hemorrhage. HHT2 results from ACVRL1 haploinsufficiency, the remaining wild-type allele being unable to contribute sufficient protein to sustain endothelial cell function. Blood vessels function normally but are prone to respond to angiogenic stimuli, leading to the development of telangiectasic lesions that can bleed. How ACVRL1 haploinsufficiency leads to pathological angiogenesis is unknown. Methods: We took advantage of Acvrl1 +/− mutant mice that exhibit HHT2 vascular lesions and focused on the neonatal retina and the airway system after Mycoplasma pulmonis infection, as physiological and pathological models of angiogenesis, respectively. We elucidated underlying disease mechanisms in vitro by generating Acvrl1 +/− mouse embryonic stem cell lines that underwent sprouting angiogenesis and performed genetic complementation experiments. Finally, HHT2 plasma samples and skin biopsies were analyzed to determine whether the mechanisms evident in mice are conserved in humans. Results: Acvrl1 +/− retinas at postnatal day 7 showed excessive angiogenesis and numerous endothelial “tip cells” at the vascular front that displayed migratory defects. Vascular endothelial growth factor receptor 1 (VEGFR1; Flt-1) levels were reduced in Acvrl1 +/− mice and HHT2 patients, suggesting similar mechanisms in humans. In sprouting angiogenesis, VEGFR1 is expressed in stalk cells to inhibit VEGFR2 (Flk-1, KDR) signaling and thus limit tip cell formation. Soluble VEGFR1 (sVEGFR1) is also secreted, creating a VEGF gradient that promotes orientated sprout migration. Acvrl1 +/− embryonic stem cell lines recapitulated the vascular anomalies in Acvrl1 +/− (HHT2) mice. Genetic insertion of either the membrane or soluble form of VEGFR1 into the ROSA26 locus of Acvrl1 +/− embryonic stem cell lines prevented the vascular anomalies, suggesting that high VEGFR2 activity in Acvrl1 +/− endothelial cells induces HHT2 vascular anomalies. To confirm our hypothesis, Acvrl1 +/− mice were infected by Mycoplasma pulmonis to induce sustained airway inflammation. Infected Acvrl1 +/− tracheas showed excessive angiogenesis with the formation of multiple telangiectases, vascular defects that were prevented by VEGFR2 blocking antibodies. Conclusions: Our findings demonstrate a key role of VEGFR1 in HHT2 pathogenesis and provide mechanisms explaining why HHT2 blood vessels respond abnormally to angiogenic signals. This supports the case for using anti-VEGF therapy in HHT2.
Long-Term Outcome after Prolonged Mechanical Ventilation. A Long-Term Acute-Care Hospital Study
Authors: Amal Jubran, Brydon J. B. Grant, Lisa A. Duffner, Eileen G. Collins, Dorothy M. Lanuza, Leslie A. Hoffman, Martin J. Tobin
Journal: American Journal of Respiratory and Critical Care Medicine (2019)

Rationale: Patients managed at a long-term acute-care hospital (LTACH) for weaning from prolonged mechanical ventilation are at risk for profound muscle weakness and disability. Objectives: To investigate effects of prolonged ventilation on survival, muscle function, and its impact on quality of life at 6 and 12 months after LTACH discharge. Methods: This was a prospective, longitudinal study conducted in 315 patients being weaned from prolonged ventilation at an LTACH. Measurements and Main Results: At discharge, 53.7% of patients were detached from the ventilator and 1-year survival was 66.9%. On enrollment, maximum inspiratory pressure (Pimax) was 41.3 (95% confidence interval, 39.4-43.2) cm H2O (53.1% predicted), whereas handgrip strength was 16.4 (95% confidence interval, 14.4-18.7) kPa (21.5% predicted). At discharge, Pimax did not change, whereas handgrip strength increased by 34.8% (P < 0.001). Between discharge and 6 months, handgrip strength increased 6.2 times more than did Pimax. Between discharge and 6 months, Katz activities-of-daily-living summary score improved by 64.4%; improvement in Katz summary score was related to improvement in handgrip strength (r = -0.51; P < 0.001). By 12 months, physical summary score and mental summary score of 36-item Short-Form Survey returned to preillness values. When asked, 84.7% of survivors indicated willingness to undergo mechanical ventilation again. Conclusions: Among patients receiving prolonged mechanical ventilation at an LTACH, 53.7% were detached from the ventilator at discharge and 1-year survival was 66.9%. Respiratory strength was well maintained, whereas peripheral strength was severely impaired throughout hospitalization. Six months after discharge, improvement in muscle function enabled patients to perform daily activities, and 84.7% indicated willingness to undergo mechanical ventilation again.
FRI0421 Toll like receptor-7/8 activation exacerbates murine experimental autoimmune myositis
Authors: R. De Lorenzo, C. Sciorati, A. Monno, M.G. Doglio, E. Rigamonti, D. Ascherman, A. Manfredi, P. Rovere-Querini
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Type I interferon (IFN)-regulated proteins are upregulated in muscle and skin tissues of patients with idiopathic inflammatory myopathies (IIM).<sup>1</sup> Type I IFN induction might rely upon the activation of toll-like receptors (TLRs).<sup>2</sup> Specifically, TLR-7/8 is indeed upregulated in infiltrating leukocytes and muscle tissue of IIM patients.<sup>3</sup> <h3>Objectives</h3> To investigate whether the activation of TLR-7/8 and type I IFN influences the natural history of the IIM. <h3>Methods</h3> Experimental autoimmune myositis (EAM) was induced by injection of the amino-terminal portion of the murine Histydil t-RNA synthetase (HisRS). Disease activity was compared in the presence or absence of the TLR-7/8 agonist R848 in wild-type mice and in mice that failed to express the IFNab receptor (IFNabR null). <h3>Results</h3> EAM induced by a single intramuscular immunisation with HisRS spontaneously abated after 7–8 weeks. In contrast, the levels of anti-HisRS autoantibodies, endomysial/perimysial leukocyte infiltration and myofiber regeneration persisted until the end of the follow-up period (22 weeks after immunisation) in mice immunised with HisRS in the presence of R848. Myofiber MHC class I molecules were detectable in HisRS +R848 immunised mice only. Muscle MHC expression occurred in parallel with leukocyte infiltration. Type I IFN was necessary for the prolonged autoantibody response to occur and for the spreading of the autoimmune response, as demonstrated using IFNabR null mice. <h3>Conclusions</h3> TLR7/8 activation is needed to induce and maintain a systemic autoimmune response against the skeletal muscle. This EAM model reproduces many characteristics of human IIM and may represent a tool for pre-clinical studies. <h3>References</h3> [1] Wenzel J, Scheler M, Bieber T, Tuting T. Evidence for a role of type I interferons in the pathogenesis of dermatomyositis. Br J Dermatol. 2005;153:462–463. [author reply 463–464] [2] Drexlerand SK, Foxwell BM. The role of toll-like receptors in chronic inflammation. Int J Biochem Cell Biol. 2010;42:506–518. [3] A. Tournadre, V. Lenief, A. Eljaafari, and P. Miossec. Immature muscle precursors are a source of interferon-beta in myositis: role of Toll-like receptor 3 activation and contribution to HLA class I up-regulation. Arthritis and rheumatism. 64:533–541 (2012). <h3>Disclosure of Interest</h3> None declared
Lgr5 Enables Positive B-Cell Selection and Tumor-Initiation in B-Cell Malignancies
Authors: Kadriye Nehir Cosgun, Gauri Deb, Xin Yang, Gang Xiao, Teresa Sadras, Franziska Auer, Jaewoong Lee, Anthony Abarientos, Maurizio Mangolini, Ali Aghajanirefah, Huimin Geng, Hassan Jumaa, Andrew G. Polson, Hans Clevers, Markus Muschen
Journal: Blood (2018)
Preference for Emicizumab over Prior Factor Treatments: Results from the HAVEN 3 and HAVEN 4 Studies
Authors: Victor Jimenez-Yuste, Midori Shima, Ido Paz-Priel, Aric Parnes, Michaela Lehle, Adam Giermasz, Avrita Campinha-Bacote, Markus Niggli, Jerzy Windyga, Sammy Chebon, Peter Trask, Johnny Mahlangu, Steven Pipe, Johannes Oldenburg
Journal: Blood (2018)
THU0501 What does trabecular bone score contribute to a fracture liaison service?
Authors: S. Ojeda, A. Naranjo, A. Saavedra, F. Santana, A. Molina, T. Marrero, O. Suarez, C. Rodriguez-Lozano
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The utility of the trabecular bone score (TBS) is controversial. <h3>Objectives</h3> To analyse the clinical usefulness of FRAX-TBS in patients with fragility fracture seen in a Fracture Liaison Service (FLS) compared to FRAX without TBS. <h3>Methods</h3> Consecutive outpatients &gt;50 y seen in our FLS were included, excluding patients admitted with hip fracture. The variables included were: age, sex, type of fracture, risk factors for FRAX, FRAX for major and hip fractures with and without TBS, bone densitometry (DXA) and indication of treatment to prevent new fractures. <h3>Results</h3> We included 251 patients, mean age 69 y, 86% women. The most frequent type of fracture was the forearm (n=122) followed by the humerus (n=64). The DXA scan results (taking the lowest value of column/hip) was osteoporosis in 41%. The average TBS was 1.307 (SD 0.103, range 0.961–1.550): forearm fracture 1.313 (SD 0.102), vertebra 1.281 (SD 0.131) and hip 1.291 (SD 0.103). 32% presented normal TBS result 53% partially degraded and 15% degraded (table 1). The results of FRAX with and without TBS were similar, with an average for major/hip fracture of 10.7/4.2 with DXA and 10.6/4.0 with TBS respectively (p&gt;0.05). A high risk of hip fracture (FRAX ≥3) was observed in 43% of patients using FRAX-DXA and 41% using FRAX-TBS. Ans a high risk of major fracture (FRAX ≥10) in 40% of patients using FRAX-DXA and 41% using FRAX-TBS. In 241 cases (96%) there was concordance in level of risk for FRAX-DXA and FRAX-TBS, while the 10 discordant cases for high risk of fracture were distributed as follows: in 6 cases FRAX-DXA was high and FRAX-TBS was normal, and in 4 cases FRAX-DXA was normal and FRAX-TBS was elevated. In our FLS, a bisphosphonate was prescribed to 169 patients (67%). Regarding patients with a low FRAX risk (n=82), in one patient FRAX-TBS was in favour of treatment. Thus, in 1/251 fractures FRAX-TBS could have influenced the treatment indication compared to FRA-DXA. <h3>Conclusions</h3> In our FLS unit, TBS does not help to classify patients' risk. The values of FRAX-TBS are similar to those of FRAX-DXA, not offering advantages when classifying patients with high risk who are candidates for treatment. <h3>Disclosure of Interest</h3> None declared
Long-Term Survivorship with Active Multiple Myeloma
Authors: Brett Grieb, Jithma Prasad Abeykoon, Saurabh Zanwar, S. Vincent Rajkumar, Martha Q. Lacy, Angela Dispenzieri, Morie A. Gertz, Wilson I Gonsalves, Ronald S. Go, Francis K. Buadi, David Dingli, Suzanne Haymann, Rahma Warsame, Taxiarchis Kourelis, Eli Muchtar, Robert A. Kyle, Shaji K. Kumar, Prashant Kapoor
Journal: Blood (2018)
DNA Methylation Subgroups in Juvenile Myelomonocytic Leukemia: An International Collaborative Analysis and Development of a Common Diagnostic Platform
Authors: Maximilian Schoenung, Elliot Stieglitz, Hideki Muramatsu, Norihiro Murakami, Mark Hartmann, Manuel Wiesenfarth, Yusuke Okuno, Adam B. Olshen, Christoph Plass, Mignon L. Loh, Charlotte Niemeyer, Christian Flotho, Daniel B. Lipka
Journal: Blood (2018)
Association of Rates of Smoking During Pregnancy With Corporate Tobacco Sales Policies
Authors: Jaclyn Hall, Hee Deok Cho, Yi Guo, Mildred M. Maldonado-Molina, Lindsay A. Thompson, Elizabeth A. Shenkman, Ramzi G. Salloum
Journal: JAMA Pediatrics (2019)

Maternal smoking during pregnancy (SDP) is a leading preventable cause of adverse birth outcomes in the United States, increasing rates of miscarriage, preterm birth, low birth weight, Sudden Infant Death Syndrome, and poor lung function. 1Despite a 28% reduction in SDP rates from 2011 to 2016, 2 tremendous disparity remains among vulnerable populations.][3] Tobacco retailer density (TRD) has been linked to high smoking rates, increased cigarette intake, low life expectancy, and high mortality. 4,5The number of tobacco retailers in the southeast United States increased by approximately 8300 in late 2012 and early 2013, when Family Dollar and Dollar General, the 2 largest dollar-store chains in the country, started selling tobacco products to meet customer demand.The number of tobacco retailers in the southeast decreased in 2014 by approximately 2500 when CVS, the largest pharmacy chain, discontinued tobacco sales.The fluctuation in TRD has affected communities differently, as CVS pharmacies are more likely to be located in urban areas, whereas dollar stores are more likely to operate in poor and rural communities. 6n this study, we examined the association between change in SDP and corporate-policy change in TRD across 6 southeastern states, controlling for rurality, poverty, social vulnerability, and tobacco-control policies.All 6 states included in this study-Florida, Georgia, Mississippi, North Carolina, South Carolina, and Tennessee-declined to adopt the Affordable Care Act Medicaid expansion in 2014, limiting access to smoking cessation and contraception programs among these states' low-income populations.
Cardiovascular Risk Factors Associated With Venous Thromboembolism
Authors: John Gregson, Stephen Kaptoge, Thomas Bolton, Lisa Pennells, Peter Willeit, Stephen Burgess, Steven Bell, Michael Sweeting, Eric B. Rimm, Christopher Kabrhel, Bengt Zöller, Gerd Assmann, Vilmundur Gudnason, Aaron R. Folsom, Volker Arndt, Astrid Fletcher, Paul E. Norman, Børge G. Nordestgaard, Akihiko Kitamura, Bakhtawar K. Mahmoodi, Peter H. Whincup, Matthew Knuiman, Veikko Salomaa, Christa Meisinger, Wolfgang Koenig, Maryam Kavousi, Henry Völzke, Jackie A. Cooper, Toshiharu Ninomiya, Edoardo Casiglia, Beatriz Rodriguez, Yoav Ben-Shlomo, Jean-Pierre Després, Leon Simons, Elizabeth Barrett-Connor, Cecilia Björkelund, Marlene Notdurfter, Daan Kromhout, Jackie Price, Susan E. Sutherland, Johan Sundström, Jussi Kauhanen, John Gallacher, Joline W. J. Beulens, Rachel Dankner, Cyrus Cooper, Simona Giampaoli, Jason F. Deen, Agustín Gómez de la Cámara, Lewis H. Kuller, Annika Rosengren, Peter J. Svensson, Dorothea Nagel, Carlos J. Crespo, Hermann Brenner, Juan R. Albertorio-Diaz, Robert Atkins, Eric J. Brunner, Martin Shipley, Inger Njølstad, Deborah A. Lawlor, Yvonne T. van der Schouw, Randi Marie Selmer, Maurizio Trevisan, W. M. Monique Verschuren, Philip Greenland, Sylvia Wassertheil-Smoller, Gordon D. O. Lowe, Angela M. Wood, Adam S. Butterworth, Simon G. Thompson, John Danesh, Emanuele Di Angelantonio, Tom Meade
Journal: JAMA Cardiology (2019)

It is uncertain to what extent established cardiovascular risk factors are associated with venous thromboembolism (VTE).
Design, synthesis and biological evaluation of chalcone analogues with novel dual antioxidant mechanisms as potential anti-ischemic stroke agents
Authors: Jiabing Wang, Lili Huang, Chanchan Cheng, Ge Li, Jingwen Xie, Mengya Shen, Qian Chen, Wulan Li, Wenfei He, Peihong Qiu, Jianzhang Wu
Journal: Acta Pharmaceutica Sinica B (2019)

Scavenging reactive oxygen species (ROS) by antioxidants is the important therapy to cerebral ischemia-reperfusion injury (CIRI) in stroke. The antioxidant with novel dual-antioxidant mechanism of directly scavenging ROS and indirectly through antioxidant pathway activation may be a promising CIRI therapeutic strategy. In our study, a series of chalcone analogues were designed and synthesized, and multiple potential chalcone analogues with dual antioxidant mechanisms were screened. Among these compounds, the most active 33 not only conferred cytoprotection of H2O2-induced oxidative damage in PC12 cells through scavenging free radicals directly and activating NRF2/ARE antioxidant pathway at the same time, but also played an important role against ischemia/reperfusion-related brain injury in animals. More importantly, in comparison with mono-antioxidant mechanism compounds, 33 exhibited higher cytoprotective and neuroprotective potential in vitro and in vivo. Overall, our findings showed compound 33 could emerge as a promising anti-ischemic stroke drug candidate and provided novel dual-antioxidant mechanism strategies and concepts for oxidative stress-related diseases treatment.
Assessment of Distal Radius Fracture Complications Among Adults 60 Years or Older
Authors: Kevin C. Chung, Sunitha Malay, Melissa J. Shauver, H. Myra Kim
Journal: JAMA Network Open (2019)

<h3>Importance</h3> Complications affect treatment outcomes and quality of life in addition to increasing treatment costs. <h3>Objectives</h3> To evaluate complication rates after the treatment of a distal radius fracture, to determine whether the rate or complication type is associated with treatment method, and to determine predictors of complications. <h3>Design, Setting, and Participants</h3> The multicenter Wrist and Radius Injury Surgical Trial (WRIST), a randomized clinical trial, enrolled participants from April 10, 2012, to December 31, 2016. The study included 304 adults 60 years or older with isolated unstable distal radius fractures; 187 were randomized and 117 opted for casting. The study was conducted at 24 health systems in the United States, Canada, and Singapore. Data for this secondary analysis were collected from April 24, 2012, to February 28, 2018. <h3>Interventions</h3> Participants opting for surgery were randomized to receive the volar locking plate system (n = 65), percutaneous pinning (n = 58), or bridging external fixation with or without supplemental pinning (n = 64). Patients who chose not to have surgery (n = 117) were not randomized and were enrolled for casting. <h3>Main Outcomes and Measures</h3> Complication rate. <h3>Results</h3> The WRIST enrolled a total of 304 participants, of whom 8 casting group participants were later found to be ineligible and were excluded from the analysis, leaving 296 participants. Randomized participants' mean (SD) age was 68 (7.2) years, 163 (87%) were female, and 165 (88%) were white. Casting participants' mean (SD) age was 75.6 (9.6) years, 93 (84%) were female, and 85 (85%) were white. The most common type of complications varied by treatment. Twelve of 65 participants (18.5%) in the internal fixation group reported a median nerve compression, while 16 of 26 participants (25.8%) who received external fixation and 13 of 56 participants (23.2%) who received pinning sustained pin site infections. Compared with the internal fixation group, complication rate for any severity complication was higher in participants who initially received casting (adjusted rate ratio, 1.88; 95% CI, 1.22-2.88), whereas the rate for moderate complications was higher in the external fixation group (adjusted rate ratio, 2.52; 95% CI, 1.25-5.09). <h3>Conclusions and Relevance</h3> The distal radius fracture treatment decision-making process for older patients should incorporate a complication profile for each treatment type. For example, external fixation and pinning could be used for patients after apprising them of pin site infection risk. Internal fixation can be done in patients with high functional demands who are willing to receive surgery. Internal fixation use should be substantiated owing to the time and cost involved. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT01589692
Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation
Authors: Ankur Varma, Neeraj Y Saini, Dawen Sui, Denái R. Milton, Omar Hasan, Akash Mukherjee, Qaiser Bashir, Gabriela Rondon, Samer A. Srour, Uday Popat, Chitra Hosing, Yago Nieto, Partow Kebriaei, Amin M. Alousi, Rohtesh S. Mehta, Issa F. Khouri, Donna M. Weber, Sheeba K. Thomas, Elisabet E. Manasanch, Hans C. Lee, Krina K. Patel, Stefan O. Ciurea, Elizabeth J. Shpall, Robert Z Orlowski, Richard E Champlin, Muzaffar H. Qazilbash
Journal: Blood (2018)
Minimal Residual Disease Evaluation Using 8-Color Flow Cytometry Predicts Risk of Relapse in High-Risk and/or Young Myeloma Patients Who Receive Bortezomib Consolidation after Frontline Tandem Transplantation
Authors: Richard Leblanc, Imran Ahmad, Rafik Terra, Séverine Landais, Céline Nkoue, Michael Sebag, Émilie Lemieux Blanchard, Nadia M. Bambace, Léa Bernard, Sandra Cohen, Jean-Sébastien Delisle, Thomas L. Kiss, Silvy Lachance, Denis-Claude Roy, Guy Sauvageau, Jean Roy
Journal: Blood (2018)